In “Genes, LDL-Cholesterol Levels, and the Central Role of LDL Receptor Activity in Heart Disease,” as well as my most recent presentations at Wise Traditions and AHS, I described the overwhelming genetic evidence for the theory that LDL receptor activity centrally governs the risk of heart disease and the large amount of other evidence from …
In a previous post, “The Great Unknown: Using the Statistics to Explore the Secret Depths of Unpublished Research,” I discussed one way a study can show something to be true when it’s false, or vice versa. If some nutrient or drug has a “true” biological effect, and we repeat many studies of the phenomenon, we …
After the Coronary Primary Prevention Trial, fittingly published in 1984, showed that cholestyramine, a drug that lowers cholesterol by causing its conversion to bile acids, could reduce the risk of heart attacks, cholesterol was widely villainized as a killer. From then on, the decades-old campaign of the American Heart Association against eggs and butter was …
by Chris Masterjohn The most recent widely publicized trial using the cholesterol-lowering statin drugs, the JUPITER trial, has been enthusiastically hailed as a justification for the expansion of these expensive drugs from people with high cholesterol levels to those who have low-grade inflammation but normal cholesterol. The study hardly justifies this enthusiasm. It does, however, …